Products with Antioxidants bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4619 | Rhamnocitrin |
| 1. Rhamnocitrin and kaempferol can augment cellular antioxidant defense capacity, at least in part, through regulation of HO-1 expression and MAPK signal transduction. 2. Rhamnocitrin and kaempferol not only protect low-density lipoprotein from oxidation but also prevent atherogenesis through suppressing macrophage uptake of oxidized low-density lipoprotein. 3. Rhamnocitrin can enhance the immune function, improve the formation of spleen cells of mice serum hemolysin of chicken red blood cell immune. 4. Rhamnocitrin shows a significant protection against cloudiness in lenses induced by hydrogen peroxide and hydrocortisone in a dose dependent manner, suggests that rhamnocitrin possesses significant anticataract activity and acts most likely due to its antioxidant property. | |
| BCN4621 | Durantoside I |
| 1. Durantoside I has inhibitory activity on the growth of lettuce seedling. 2. Durantoside I displays DPPH scavenging activity. | |
| BCN4629 | Olivetol |
| Olivetol is a precursor in various syntheses of tetrahydrocannabinol. It acts as a competitive inhibitor of the cannabinoid receptors CB1 and CB2. Olivetol has antioxidant effects. | |
| BCN4640 | Cycloheterophyllin |
| 1. Cycloheterophyllin exerts a concentration-dependent inhibition of neutrophil cytosolic protein kinase C (PKC) and rat brain PKC by the O2- generation in rat neutrophils, but has no effect on porcine heart protein kinase A (PKA). 2. Cycloheterophyllin has an antioxidant effect and can effectively scavenge free radicals. 3. Cycloheterophyllin is a photoprotective agent that inhibits ultraviolet A (UVA)-induced oxidative stress and damage, and could be used in the research on and prevention of skin photoaging. 4. Cycloheterophyllin shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation, due to an inhibitory effect on cyclooxygenase. | |
| BCN4641 | Hexahydrocurcumin |
| 1. Hexahydrocurcumin has cytotoxic effect, may prove useful in cancer prevention. 2. Hexahydrocurcumin together with 5-fluorouracil exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer. 3. Hexahydrocurcumin is an anti-atherosclerogenic agent in humans, can inhibit platelet aggregation in the treatment of human platelet-rich plasma. 4. Hexahydrocurcumin has in vitro antioxidant and anti-inflammatory activities, it has potential beneficial effects as a food and/or dietary supplement. | |
